870 related articles for article (PubMed ID: 17084534)
1. Molecular mechanisms of resistance and toxicity associated with platinating agents.
Rabik CA; Dolan ME
Cancer Treat Rev; 2007 Feb; 33(1):9-23. PubMed ID: 17084534
[TBL] [Abstract][Full Text] [Related]
2. Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.
Muggia FM; Bonetti A; Hoeschele JD; Rozencweig M; Howell SB
J Clin Oncol; 2015 Dec; 33(35):4219-26. PubMed ID: 26503202
[No Abstract] [Full Text] [Related]
3. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
4. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?
Lokich J
Cancer Invest; 2001; 19(7):756-60. PubMed ID: 11577818
[No Abstract] [Full Text] [Related]
5. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
6. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based drugs: past, present and future.
Dilruba S; Kalayda GV
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
[TBL] [Abstract][Full Text] [Related]
8. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
9. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
Bruno PM; Liu Y; Park GY; Murai J; Koch CE; Eisen TJ; Pritchard JR; Pommier Y; Lippard SJ; Hemann MT
Nat Med; 2017 Apr; 23(4):461-471. PubMed ID: 28263311
[TBL] [Abstract][Full Text] [Related]
10. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
12. [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].
Goncharova SA; Raevskaia TA; Iakushchenko TN; Blokhina SV; Konovalova NP; Sen' VD
Vopr Onkol; 2011; 57(3):355-8. PubMed ID: 21882607
[TBL] [Abstract][Full Text] [Related]
13. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
16. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
Saintas E; Abrahams L; Ahmad GT; Ajakaiye AM; AlHumaidi AS; Ashmore-Harris C; Clark I; Dura UK; Fixmer CN; Ike-Morris C; Mato Prado M; Mccullough D; Mishra S; Schöler KM; Timur H; Williamson MD; Alatsatianos M; Bahsoun B; Blackburn E; Hogwood CE; Lithgow PE; Rowe M; Yiangou L; Rothweiler F; Cinatl J; Zehner R; Baines AJ; Garrett MD; Gourlay CW; Griffin DK; Gullick WJ; Hargreaves E; Howard MJ; Lloyd DR; Rossman JS; Smales CM; Tsaousis AD; von der Haar T; Wass MN; Michaelis M
PLoS One; 2017; 12(2):e0172140. PubMed ID: 28192521
[TBL] [Abstract][Full Text] [Related]
18. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
